Showing 7211-7220 of 10171 results for "".
- Celgene to Present Data From Abraxane Melanoma Studyhttps://practicaldermatology.com/news/20121009-celgene_to_present_data_from_abraxane_melanoma_study/2459712/Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-fre
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Lumiere Medical Announces Dinner Serieshttps://practicaldermatology.com/news/20121003-lumiere_medical_announces_dinner_series/2459715/Lumiere Medical's Innovative MD Academy Regional Dinner Series will be held through the month of October. The company invites physician and medical spa owners to learn about the future of anti-aging and body contouring, w
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Stiefel/GSK Receives FDA Approval of Sorilux Foam, 0.005%https://practicaldermatology.com/news/20121002-stiefel_receives_fda_approval_of_sorilux_foam_0005/2459719/The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Sorilux (calcipotriene) Foam, 0.005% from Stiefel/GSK. The sNDA expands the indication for Sorilux Foam to include the topical treatment of plaque psor
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- Star Scientific's Rock Creek Pharmaceuticals, Inc. Launches New Producthttps://practicaldermatology.com/news/20120926-star_scientifics_rock_creek_pharmaceuticals_inc_launches_new_product/2459728/Star Scientific, Inc., through its wholly owned subsidiary Rock Creek Pharmaceuticals, Inc., announced the new Anatabloc face cream, which is available on the cosmetic portion of the Anatabloc website and in select dermatology practices. The pro
- CMS Provider Call Today on EHRshttps://practicaldermatology.com/news/20120913-cms_provider_call_today_on_ehrs/2459740/The Centers for Medicare and Medicaid Services will host a 90-minute National Provider Call today, Sept. 13, to discuss the final rule for the Stage 2 electronic health records meaningful use program. The call is free, but prior registration is required.
- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA